Everolimus for Children With Recurrent or Progressive Ependymoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel C Bowers, MD
UT Southwestern Medical Center at Dallas, Dallas, TX
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lucile Packard Children'S Hospital Stanford University
Stanford, California, United States
- New York University Stephen D. Hassenfeld Children'S Center for Cancer & Blood Disorders
New York, New York, United States
- Ut Southwestern Medical Center / Children'S Medical Center
Dallas, Texas, United States
- Baylor College of Medicine / Texas Children'S Hospital
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2015
- Primary completion
- 14 Jul 2023
- Completion
- 14 Jul 2023
- Last update posted
- 8 May 2024
- Registered enrollment
- 11
- Registry id
- NCT02155920
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.